Daniel M. Van Handel
Expertise in
5
conditions

Dr. Daniel M. Van Handel

Gastroenterology
MNGI Digestive Health - Plymouth
15700 37th Avenue North, Suite 300, 
Plymouth, MN 
Accepting New Patients
Offers Telehealth
Expertise in
5
conditions
MNGI Digestive Health - Plymouth
15700 37th Avenue North, Suite 300, 
Plymouth, MN 

Overview

Daniel Van Handel is a Gastroenterologist practicing medicine in Plymouth, Minnesota.

Dr. Van Handel is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Necrotizing Enterocolitis, Pseudomembranous Colitis, Crohn's Disease, Endoscopy, and Colonoscopy.

Dr. Van Handel is board certified in American Board Of Internal Medicine,2011 and Gastroenterology. He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 7 clinical trials. Dr. Van Handel is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in MN

Board Certifications

American Board Of Internal Medicine,2011
Gastroenterology

Hospital Affiliations

Mercy Hospital
North Memorial Health Hospital
Maple Grove Hospital
M Health Fairview Southdale Hospital
Abbott Northwestern Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Metropolitan Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PreferredOne
  • HMO
  • OTHER COMMERCIAL
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

MNGI Digestive Health - Plymouth
15700 37th Avenue North, Suite 300, Plymouth, MN 55446

Additional Areas of Focus

Dr. Van Handel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
View 4 Less Clinical Trials

5 Total Publications

Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.
Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies.
Journal: Infectious diseases and therapy
Published: February 25, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Martin L. Freeman
Gastroenterology
Expertise in
25
conditions
Dr. Martin L. Freeman
Gastroenterology
Referral may be required

M Health Fairview Pancreas And Biliary Clinic Minneapolis

909 Fulton Street Southeast, Floor 4, 
Minneapolis, MN 
 (13.3 miles away)
612-624-9709
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Martin Freeman is a Gastroenterologist practicing medicine in Minneapolis, Minnesota. Dr. Freeman is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Chronic Pancreatitis, Hereditary Pancreatitis, Acute Pancreatitis, Pancreatectomy, and Islet Cell Transplantation. Dr. Freeman is board certified in Gastroenterology: American Board Of Internal Medicine, 1987 and Internal Medicine: American Board Of Internal Medicine, 1983. Dr. Freeman is currently accepting new patients.

Expertise in
25
conditions
Dr. Guru V. Trikudanathan
Gastroenterology
Expertise in
25
conditions
Dr. Guru V. Trikudanathan
Gastroenterology
Referral may be required

M Health Fairview Pancreas And Biliary Clinic Minneapolis

909 Fulton Street Southeast, Floor 4, 
Minneapolis, MN 
 (13.3 miles away)
612-624-9709
Experience:
18+ years
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Guru Trikudanathan is a Gastroenterologist practicing medicine in Minneapolis, Minnesota. He has been practicing medicine for over 18 years. Dr. Trikudanathan is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hereditary Pancreatitis, Acute Pancreatitis, Chronic Pancreatitis, Pancreatectomy, and Islet Cell Transplantation. Dr. Trikudanathan is currently accepting new patients.

Expertise in
12
conditions
Dr. Aasma P. Shaukat
Gastroenterology
Expertise in
12
conditions
Dr. Aasma P. Shaukat
Gastroenterology
Referral may be required

Minneapolis Veterans Administration Hospital

1 Veterans Dr, 
Minneapolis, MN 
 (16.9 miles away)
612-467-2000
Languages Spoken:
English
See accepted insurances

Aasma Shaukat is a Gastroenterologist practicing medicine in Minneapolis, Minnesota. Dr. Shaukat is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Colorectal Polyps, Juvenile Polyposis Syndrome, Colonoscopy, and Endoscopy.

Frequently Asked Questions about Dr. Daniel M. Van Handel

How do I make an appointment with Dr. Daniel M. Van Handel?

You can book an appointment with Dr. Daniel M. Van Handel by calling their office at 612-871-1145. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel M. Van Handel a top-rated expert for Necrotizing Enterocolitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel M. Van Handel is classified as an Advanced expert for Necrotizing Enterocolitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel M. Van Handel specialize in?

While Dr. Daniel M. Van Handel is a Gastroenterology, they have specific expertise in Necrotizing Enterocolitis, Pseudomembranous Colitis, and Crohn's Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Daniel M. Van Handel participate in research or clinical trials?

Yes. Dr. Daniel M. Van Handel has published 5 articles and abstracts on conditions like Necrotizing Enterocolitis. You can view a list of Dr. Daniel M. Van Handel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel M. Van Handel accept my insurance?

Dr. Daniel M. Van Handel accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 612-871-1145 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Van Handel's expertise for a condition
ConditionClose
      View All 27 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile